@eyeswideopen for clarity, I believe that your list is by revenue?
Novartis has a market cap of around $200 billion on revenue of around $48 billion. Top J&J as you show market cap $400 billion double Novartis, revenue only about $9 billion more.
What I find interesting (if I have the correct figures) is that Entresto accounted for nearly $2.5 Billion of those Norvartis sales. The first choice heart treatment option, 45% growth whereas overall company managed net sales growth of 3% (I believe)
So where can they find new therapies to drive a similar double digit growth as Entresto and close that gap with J&J?
Any suggestions, I am sure you can reach them in Switzerland.
regards
Yelrom
Mesoblast Partnership Announcements, page-84
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
0.080(8.25%) |
Mkt cap ! $1.198B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.06 | 99.0¢ | $4.930M | 4.779M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 23545 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 339479 | 5 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |